ArticleRadiation oncology (London, England)2025
Multiple brain metastases: resection with IORT versus adjuvant radiotherapy and concurrent irradiation of unresected lesions.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment of multiple brain metastases (BM) often involves surgical resection of one lesion combined with stereotactic radiotherapy (SRT) to the resection cavity and unresected BM. Intraoperative radiotherapy (IORT) is an emerging alternative for treating the resection cavity, potentially dosimetric benefits. This study aimed to compare the dosimetry of treating the resection cavity with IORT versus adjuvant SRT when combined with SRT for additional unresected BM.
methodsTen patients with BM who received adjuvant SRT to the resection cavity plus concurrent SRT to additional BM (adjuvant SRT + SRT to BM group) and 4 patients with IORT and SRT to BM were identified. Post-hoc IORT plans were calculated for IORT patients and summed with corresponding SRT plans. Additionally, patients from the adjuvant SRT + SRT to BM group served as templates for IORT simulation and the simulated IORT plans were also summed with the corresponding plans for SRT to residual BM. The simulated IORT cases were then pooled with the actual IORT cases, forming the IORT + SRT to BM group. Brain dose exposure (V12Gy, V18Gy, V20Gy, V24Gy, V25Gy, and V30Gy) and maximum doses (D0.035 cm³) to the brainstem and optic tract were evaluated.
resultsThe IORT + SRT to BM group showed significantly lower brain dose exposure across all metrics (V12Gy-V30Gy) compared to the adjuvant SRT + SRT to BM group (p < 0.05 for all). Maximum doses to organs at risk were lower in the IORT + SRT to BM group, with mean D0.035 cm³ reduced by 37.7% for the brainstem (3.51 Gy vs. 5.65 Gy, p = 0.292) and significantly reduced by 57.5% for the optic tract (0.89 Gy vs. 2.10 Gy, p = 0.040).
conclusionsIORT in combination with SRT for additional BM demonstrated superior dosimetric properties compared to adjuvant cavity SRT plus concurrent SRT to BM.
trial registrationNot applicable (Retrospective dosimetric study).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.